285 related articles for article (PubMed ID: 35640776)
1. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
[TBL] [Abstract][Full Text] [Related]
2. Selenium nanoparticles and quercetin suppress thioacetamide-induced hepatocellular carcinoma in rats: Attenuation of inflammation involvement.
Mohamed AA; Zaghloul RA; Abdelghany AM; El Gayar AM
J Biochem Mol Toxicol; 2022 Apr; 36(4):e22989. PubMed ID: 35179263
[TBL] [Abstract][Full Text] [Related]
3. Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7.
Yousef EH; Abo El-Magd NF; El Gayar AM
Life Sci; 2023 Jul; 324():121735. PubMed ID: 37142088
[TBL] [Abstract][Full Text] [Related]
4. Antineoplastic Activity of Chrysin against Human Hepatocellular Carcinoma: New Insight on GPC3/SULF2 Axis and lncRNA-AF085935 Expression.
Sherif IO; Al-Mutabagani LA; Sabry D; Elsherbiny NM
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076548
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles Loaded with GSK1059615 Combined with Sorafenib Inhibited Programmed Cell Death 1 Ligand 1 Expression by Negatively Regulating the PI3K/Akt/NF-
Zhou S; Ma Y; Xu R; Tang X
J Biomed Nanotechnol; 2022 Mar; 18(3):693-704. PubMed ID: 35715918
[TBL] [Abstract][Full Text] [Related]
6. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
7. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
Jing W; Shuo L; Yingru X; Min M; Runpeng Z; Jun X; Dong H
Biochem Biophys Res Commun; 2019 Oct; 519(1):41-45. PubMed ID: 31481232
[TBL] [Abstract][Full Text] [Related]
8. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.
Cheng Z; Ni Q; Qin L; Shi Y
Braz J Med Biol Res; 2021; 54(9):e10390. PubMed ID: 34076140
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
11. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
[TBL] [Abstract][Full Text] [Related]
13. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
14. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
15. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
17. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
[TBL] [Abstract][Full Text] [Related]
18. Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy.
Zheng L; Li C; Huang X; Lin X; Lin W; Yang F; Chen T
Biomaterials; 2019 Sep; 216():119220. PubMed ID: 31200144
[TBL] [Abstract][Full Text] [Related]
19. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
20. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]